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Abstract
Upon contact with human plasma, bacteria are rapidly recognized by the complement system that labels their surface for
uptake and clearance by phagocytic cells. Staphylococcus aureus secretes the 16 kD Extracellular fibrinogen binding protein
(Efb) that binds two different plasma proteins using separate domains: the Efb N-terminus binds to fibrinogen, while the C-
terminus binds complement C3. In this study, we show that Efb blocks phagocytosis of S. aureus by human neutrophils. In
vitro, we demonstrate that Efb blocks phagocytosis in plasma and in human whole blood. Using a mouse peritonitis model
we show that Efb effectively blocks phagocytosis in vivo, either as a purified protein or when produced endogenously by S.
aureus. Mutational analysis revealed that Efb requires both its fibrinogen and complement binding residues for phagocytic
escape. Using confocal and transmission electron microscopy we show that Efb attracts fibrinogen to the surface of
complement-labeled S. aureus generating a ‘capsule’-like shield. This thick layer of fibrinogen shields both surface-bound
C3b and antibodies from recognition by phagocytic receptors. This information is critical for future vaccination attempts,
since opsonizing antibodies may not function in the presence of Efb. Altogether we discover that Efb from S. aureus
uniquely escapes phagocytosis by forming a bridge between a complement and coagulation protein.
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Introduction
Phagocytosis by neutrophils is crucial to the host innate defense
against invading bacteria since it leads to intracellular destruction
of bacteria by production of oxygen radicals and proteolytic
enzymes [1]. Bacterial engulfment by neutrophils is strongly
enhanced by the labeling or ‘opsonization’ of bacteria with plasma
factors such as antibodies and complement activation products
(C3b, iC3b) [2]. Complement activation takes place at the
bacterial surface and is initiated by recognition molecules (C1q,
Mannose Binding Lectin (MBL)) that interact with bacterial
surface structures like sugars or proteins [3]. Complement
activation occurs through three different pathways (classical, lectin
and alternative) that converge in the formation of C3 convertase
enzymes that cleave the central complement protein C3 [4]. This
cleavage step leads to massive decoration of the bacterial surface
with covalently deposited C3b and iC3b molecules, which are
recognized by complement receptor 1 and 3 (CR1 and CR3) on
neutrophils. Complement activation proceeds by formation of C5
convertase enzymes that cleave C5 to release the potent
chemoattractant C5a and C5b, which initiates formation of the
membrane attack complex [5].
Staphylococcus aureus is an important human pathogen notorious
for its ability to cause both community- and hospital-acquired
diseases, ranging from mild skin infections to bacteremia, sepsis
and endocarditis [6]. Although Methicillin-resistant S. aureus
(MRSA) was previously considered as an opportunistic pathogen
causing hospital-acquired infections in immune-compromised
patients, the emergence of the highly virulent community-
associated MRSA showed that this bacterium could also cause
serious infections in otherwise healthy persons [7]. Due to the
rapid emergence of antibiotic resistance strains, alternative therapy
options are now being explored [8]. Vaccination has not been
successful so far and an important reason may be the bacteria’s
elaborate immune evasion repertoire. Therefore, immune evasion
proteins are now considered as important vaccination targets [9].
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One proposed vaccine candidate is Extracellular fibrinogen
binding protein (Efb), a 16-kD secreted protein with a presumable
role in disease pathogenesis [10,11], which is found in 85% of S.
aureus strains [12]. Efb consists of two functionally distinct
domains: a disordered 9 kD N-terminus (Efb-N) that harbors
two binding sites for fibrinogen (Fg) [13] and a folded 7 kD C-
terminus (Efb-C) that binds to the C3d domain of complement C3
(which is also present in C3b and iC3b) [14,15]. Although previous
papers described various functions for the isolated N- and C-
terminal domains of Efb [12–19], it is currently not understood
why the full-length Efb protein harbors both a Fg and C3d binding
site. In this study we demonstrate that Efb potently blocks
phagocytosis of bacteria via a novel mechanism linking the
complement and coagulation proteins.
Results
Full-length Efb inhibits phagocytosis in the presence of
plasma
To study a potential role for full-length Efb in phagocyte escape,
we mixed fluorescently labeled S. aureus with purified human
neutrophils, Efb (0.5 mM) and human serum or plasma as a source
for complement and analyzed bacterial uptake by flow cytometry.
In the presence of serum, Efb did not affect bacterial uptake by
neutrophils (Fig. 1A). However when we used human plasma as a
complement source, we found that Efb strongly prevented
phagocytosis (Fig. 1A,B) and subsequent bacterial killing by
neutrophils (Supplemental Fig. S1). Phagocytosis inhibition in
plasma occurred in a dose-dependent fashion with a calculated
IC50 of 0.08 mM (Fig. 1C). Since the main difference between
plasma and serum lies in the presence of coagulation proteins, we
investigated whether the observed differences in phagocytosis
inhibition were caused by the fact that serum lacks Fg. Indeed, we
observed that supplementation of serum with physiological
concentrations of Fg led to phagocytosis inhibition by Efb
(Fig. 1D). Fg is a large (340 kD) dimeric protein that comprises
one central E-fragment and two lateral D-fragments. Since Efb
binds to the D-fragment of Fg [13], we examined if supplementing
serum with Fg-D would also lead to phagocytosis inhibition by
Efb. Interestingly, we found that Efb could not block phagocytosis
in the presence of Fg-D (Fig. 1E) indicating that full-length Fg is
required for phagocytosis inhibition by Efb. Since Fg is a ligand for
CR3 (or Mac-1 [20]) on neutrophils, we studied whether the
binding of Fg to this receptor is important for the anti-phagocytic
effect of Efb. Therefore, we purified Fg from wild-type mice or
Fgc390–396A (DMac-1 Fg) mice that express a mutated form of Fg
lacking the Mac-1 binding site but retaining clotting function [21].
Fig. 1F shows that supplementation of human serum with both
forms of mouse Fg led to inhibition by Efb, indicating that Fg
binding to Mac-1 is not important for inhibition. In conclusion,
Efb interferes with phagocytosis in a plasma environment and the
presence of full-length Fg is required for this inhibition.
Simultaneous binding to Fg and C3 is essential for
phagocytosis inhibition by Efb
To get more insight into the mechanism of inhibition, we
constructed a panel of Efb mutants (Fig. 2A). First we observed
that the individual N- or C-termini of Efb could not block
phagocytosis in plasma (Fig. 2B). In addition, mixing the N- and
C-terminal fragments of Efb did not markedly affect phagocytosis,
indicating that full-length Efb is required. Second, we generated
mutants of full-length Efb lacking the previously characterized
binding sites for Fg and C3 (Fig. 2A [13,14]). We created three
different Fg-binding mutants: EfbDFg1 lacking residues 30–45,
EfbDFg2 lacking residues 68–76 and EfbDFg1+2 lacking both
these Fg binding sites. Furthermore we created EfbDC3 in which
the C3d-binding residues R131 and N138 were each replaced with
a glutamic acid (E) (also known as Efb-RENE [14]). Using direct
binding ELISAs we verified that EfbDFg1+2 could no longer bind
Fg, while the single EfbDFg1 and EfbDFg2 mutants and EfbDC3
still bound Fg (Supplemental Fig. S2A). As expected, all mutants
except EfbDC3 bound to C3b (Supplemental Fig. S2B). Next, we
compared these mutants in the neutrophil phagocytosis assay in
the presence of human plasma. We show that EfbDFg1+2 and
EfbDC3 could no longer block phagocytosis (Fig. 2C), indicating
that a simultaneous interaction with both Fg and complement C3
(products) is essential for the anti-phagocytic action of Efb. The
finding that EfbDFg1 and EfbDFg2 were still active indicates that
Efb requires only one of its two Fg binding sites to block
phagocytosis.
Efb blocks phagocytosis ex vivo and in vivo
To study whether Efb can also block phagocytosis in a natural
environment, we tested its activity in ex vivo and in vivo phagocytosis
models. In an ex vivo human whole blood model, we incubated
fluorescent S. aureus with 50% human whole blood and Efb. After
25 minutes, neutrophil phagocytosis was analyzed by flow
cytometry. We observed that full-length Efb potently blocked
phagocytosis by human neutrophils in whole blood (Fig. 3A) and
that this inhibition depends on the interaction of Efb with both Fg
and C3. Next, we studied phagocytosis of S. aureus in an in vivo
mouse peritonitis model. To this end, mice were treated with
carrageenan intraperitoneally (i.p.) to induce neutrophil infiltration
into the peritoneal cavity and subsequently challenged with 108
heat-inactivated fluorescent S. aureus in the presence or absence of
Efb (1 mM). One hour later, mice were sacrificed and the
peritoneum was lavaged with sterile PBS. Neutrophils were
stained and phagocytosis of fluorescent bacteria was analyzed by
flow cytometry. We observed that Efb blocked phagocytosis in the
peritoneum (Fig. 3B,C). Efb mutants showed that inhibition of
phagocytosis in vivo also depends on the Fg and C3 binding
domains of Efb.
Author Summary
Staphylococcus aureus is a leading cause of severe bacterial
infections in both hospital and community settings. Due to
its increasing resistance to antibiotics, development of
additional therapeutic strategies like vaccination is re-
quired to control this pathogen. Vaccination attempts
against S. aureus have not been successful so far and an
important reason may be the pathogen’s elaborate
repertoire of molecules that dampen the immune re-
sponse. These evasion molecules not only suppress natural
immunity but also hamper the current attempts to create
effective vaccines. In this paper, we describe a novel
mechanism by which S. aureus can prevent uptake by
phagocytic immune cells. We discover that the secreted S.
aureus protein Extracellular fibrinogen binding protein
(Efb) generates a ‘capsule’-like shield around the bacterial
surface through a dual interaction with the plasma
proteins complement C3b and fibrinogen. The Efb-depen-
dent fibrinogen shield masks important opsonic molecules
like C3b and antibodies from binding to phagocyte
receptors. This information is critical for future vaccination
attempts, since opsonizing antibodies may not function in
the presence of this anti-phagocytic shield.
Anti-phagocytic Properties of Efb
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Phagocytosis inhibition by Efb is independent of
complement inhibition
Experiments shown above indicate that Efb requires an
interaction with both complement and Fg to block phagocytosis.
To study whether Efb also interacts with S. aureus specifically, we
analyzed whether purified Efb can block phagocytosis of other
bacteria as well. Fluorescent S. epidermidis or E. coli were mixed with
human plasma and phagocytosis by neutrophils was evaluated. Efb
potently inhibits the uptake of these bacteria as well, indicating
that Efb can block phagocytosis independently of S. aureus (Fig. 4A).
Previously, we observed that the C-terminal domain of Efb is a
complement inhibitor that inactivates C5 convertases to prevent
cleavage of C5 [12]. Efb-C did not affect C3b labeling of bacteria
in conditions where all complement pathways are active.
However, since the effects of Efb on complement inhibition were
performed with serum instead of plasma, we wondered whether
full-length Efb might affect C3b labeling of bacteria in a plasma
environment. Therefore, we incubated S. aureus with human
plasma and Efb and quantified surface-bound C3b using
immunoblotting. As a control, we added EDTA to prevent
activation of all complement routes (which are calcium and
magnesium dependent). Similar amounts of C3b were found on
the bacterial surface in the presence of Efb compared to buffer
(Fig. 4B), indicating that Efb does not interfere with C3b labeling
in plasma. Subsequently, we re-analyzed the inhibition of C5
convertases by Efb (mutants) in plasma using an alternative
pathway hemolytic assay. Rabbit erythrocytes were incubated with
human plasma and C5 cleavage was measured by means of C5b-9
dependent lysis of erythrocytes. In conjunction with previous
results in serum, we found that all Efb mutants except for EfbDC3
inhibited C5 cleavage in plasma (Fig. 4C). Since this inhibition
exclusively depends on the C-terminal domain (all Fg binding
mutants of Efb could still block C5 cleavage), this proves that
interference with C5 cleavage is at least not sufficient for
phagocytosis inhibition by Efb. To further show that the effects
of Efb on complement activation are dispensable for phagocytosis
inhibition, we introduced a washing step in our phagocytosis assay.
Bacteria were first incubated with serum (in the absence of Efb) to
deposit C3b. After washing away unbound serum proteins
(including C5a), these pre-opsonized bacteria were incubated with
Fg and neutrophils. In this assay, Efb could potently block
phagocytosis (Fig. 4D). In conclusion, these results indicate that the
anti-phagocytic activity of Efb is not related to its complement-
inhibitory effect.
Efb covers S. aureus with a shield of Fg
We wondered whether Efb might bind to C3b-labeled bacteria
and then attract Fg to the surface. First, we studied whether full-
length Efb can bind to Fg and C3b at the same time. C3b-coated
microtiter plates were incubated with Efb and, after a washing
step, treated with Fg. Fig. 5A shows that Efb is able to form a
complex with C3b and Fg. Also, the EfbDFg1 and EfbDFg2
mutants could still form Fg-C3b complexes. In contrast, complex
formation was not detected for the mutants that lack either both
Fg (EfbDFg1+2) or the C3 binding domains (EfbDC3) (Fig. 5A).
Then, we investigated whether Efb could attract Fg to pre-
opsonized bacteria. Therefore, S. aureus was pre-opsonized with
human serum to deposit complement and subsequently incubated
with Efb. After washing, bacteria were incubated with Alexa-
488 conjugated Fg. Using both flow cytometry and confocal
Figure 1. Full-length Efb inhibits phagocytosis of S. aureus in human plasma. A. Phagocytosis of fluorescently labeled S. aureus by purified
human neutrophils in the presence of human serum or plasma and Efb (0.5 mM). B. Histology image of human neutrophils incubated with S. aureus
and 2.5% plasma in the presence or absence of Efb (0.5 mM). Cells were stained using Diff-Quick. C. Dose-dependent phagocytosis inhibition by Efb in
the presence of 2.5% human plasma. IC50 was calculated using non-linear regression analysis, R
2 = 0.95. D–F. Phagocytosis in the presence of 5%
human serum supplemented with either full-length human Fg (Fig. 1D), the D domain of human Fg (1 mM or 86 mg/ml) (Fig. 1E) or mouse Fg (WT or
lacking the Mac-1 binding site) (Fig. 1F). A, C–F are mean6 se of three independent experiments. B is a representative image. *P,0.05, **P,0.005 for
Efb versus buffer (two-tailed Student’s t-test).
doi:10.1371/journal.ppat.1003816.g001
Anti-phagocytic Properties of Efb
PLOS Pathogens | www.plospathogens.org 3 December 2013 | Volume 9 | Issue 12 | e1003816
microscopy we observed that Efb mediates Fg binding to pre-
opsonized bacteria (Fig. 5B,C). Consistent with the ELISA data for
complex formation, no Fg binding was detected in the presence of
EfbDFg1+2 or EfbDC3. Confocal analyses indicated that Efb
covers the complete bacterial surface with Fg (Fig. 5C). Using
Transmission Electron Microscopy we analyzed this Fg layer
created by Efb in more detail. After incubation of S. aureus with
plasma and Efb, we observed a diffuse outer layer formed around
the bacteria (Fig. 5D). Altogether these experiments show that Efb
binds to C3b on the bacterial surface and subsequently attracts Fg
forming a shield around the bacterial surface.
Efb blocks recognition of C3b and IgG on the surface
Since Efb covers bacteria with a shield of Fg, we hypothesized
that this would frustrate the binding of phagocytic receptors to
their ligands on the bacterial surface Using flow cytometry, we first
analyzed whether C3b-labeled bacteria were still recognized by
CR1. Pre-opsonized S. aureus was incubated with soluble CR1 in
Figure 2. Simultaneous binding to Fg and C3 is essential for phagocytosis inhibition by Efb. A. Schematic overview of Efb mutants
generated in this study. Efb is depicted in its secreted form (30–165) lacking the signal peptide (1–29). Bounding boxes indicate Fg- and C3-binding
domains. The N-terminus of Efb (light grey, 9 kD) harbors two Fg binding sites named Fg1 (residues 30–67) and Fg2 (residues 68–98). The C-terminus
of Efb (dark grey, 7 kD) harbors the C3 binding site (residues R131 and N138). EfbDFg1 has deletion of residues 30–45, resulting in non-functional
binding Fg1; whereas EfbDFg2 has deletion of residues 68–76, resulting in non-functional binding Fg2. B–C. Phagocytosis of fluorescent S. aureus by
human neutrophils in the presence of 5% human plasma and Efb fragments (B) or Efb mutants (C) (all at 1 mM). B,C are mean 6 se of three
independent experiments. **P,0.005 for Efb versus buffer (two-tailed Student’s t-test).
doi:10.1371/journal.ppat.1003816.g002
Anti-phagocytic Properties of Efb
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the presence of Fg and Efb. Clearly, binding of CR1 to pre-
opsonized bacteria was blocked by the presence of both Fg and
Efb (Fig. 6A). Addition of Fg or Efb alone did not affect CR1
binding. Next, we investigated whether the Fg shield specifically
blocks C3b-CR1 interactions or whether it also disturbs the
binding of neutrophil Fc receptors to opsonic antibodies. To
analyze this, we determined whether the Fc part of bacterium-
bound IgG could still be recognized by specific antibodies. We
found that incubation of pre-opsonized bacteria with Efb and Fg
disturbs recognition of the antibody Fc domain on the surface
(Fig. 6B), suggesting that Fc receptors can no longer recognize
their target. This information is crucial for future vaccine
development since opsonic antibodies against S. aureus may not
function when Efb hides these antibodies underneath an Fg shield.
To further prove that Efb functionally blocks opsonization, we
analyzed phagocytosis of an encapsulated S. aureus strain in the
presence or absence of anti-capsular antibodies. The encapsulated
S. aureus strain Reynolds was grown for 24 hours in Columbia agar
supplemented with 2% NaCl (for optimal capsule expression [22])
and subsequently labeled with FITC. We verified capsule
expression after FITC-labeling using specific antibodies (Supple-
mental Fig. S3). In low plasma concentrations (0–1%), we
observed that anti-capsular antibodies caused a 6-fold increase
in phagocytic uptake of encapsulated S. aureus (Fig. 6C). At these
Figure 3. Purified Efb blocks phagocytosis ex vivo and in vivo. A. Ex vivo phagocytosis of fluorescent S. aureus incubated with 50% human
whole blood and Efb (1 mM). Neutrophils were gated based on forward and side scatter properties. B. In vivo phagocytosis of fluorescent S. aureus by
human neutrophils in the mouse peritoneum. Neutrophils were attracted to the peritoneal cavity using carrageenan (i.p.) and subsequently
challenged with 108 heat-inactivated fluorescent S. aureus and Efb (1 mM) for 1 hour. The peritoneal lavage was collected and neutrophil
phagocytosis was analyzed by flow cytometry. Neutrophils were gated based on Gr-1 expression. The mouse experiments were carried out three
times. In each experiment, we used 3 mice per group and the cells of these 3 mice were pooled for phagocytosis analysis. C. Representative
histograms of B. A,B are mean 6 se of three independent experiments. *P,0.05, **P,0.005 for Efb versus buffer (two-tailed Student’s t-test).
doi:10.1371/journal.ppat.1003816.g003
Anti-phagocytic Properties of Efb
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plasma concentrations, Efb could not block phagocytosis. How-
ever at higher plasma concentrations (3% and more), Efb potently
impeded phagocytosis in the presence of anti-capsule antibody
(Fig. 6C). These data support our idea that the Fg shield created
by Efb prevents recognition of important opsonins like C3b and
IgG, also in the context of a capsule-expressing strain that is
targeted by specific antibodies.
Endogenous Efb blocks phagocytosis in vitro and in vivo
To study whether endogenous expression of Efb leads to
impaired phagocytosis of S. aureus via complex formation, we
extended our analyses with (supernatants of) an isogenic Efb-
deletion mutant in S. aureus Newman (previously described in [23]).
First we performed Immunoblotting to semi-quantify the produc-
tion levels of Efb in liquid bacterial culture supernatants.
Supernatants of wild-type (WT) S. aureus Newman were subjected
to Immunoblotting and developed using polyclonal anti-Efb
antibodies (Fig. 7A). Efb expression in the supernatant was
quantified using ImageJ software and compared with fixed
concentrations of purified (His-tagged) Efb using linear regression
analysis (R2 = 0.986). Efb levels in 4 h and 20 h supernatants
contained 1,1 mM and 0,9 mM Efb respectively. Although the Efb
levels in strain Newman are suspected to be higher than in other S.
aureus strains (up to 10-fold [24], due to a point mutation in the
SaeR/S regulatory system that drives expression of immune
evasion genes [25]), the fact that these levels are .10 times higher
than the calculated IC50 needed for phagocytosis inhibition
(0.08 mM, Fig. 1C), suggests that Efb concentrations required for
phagocytosis inhibition can be reached in vivo. In a separate
Immunoblot, we checked for the presence of Efb in 4 h
supernatants of the WT, Efb-deficient (DEfb) and the comple-
mented strain (DEfb+pEfb) confirming the lack of Efb expression
in the mutant (Fig. 7A). Next we used these supernatants to study
whether endogenous Efb can mediate C3b-Fg complex formation
on the bacterial surface. S. aureus was first incubated with serum to
deposit C3b, then mixed with bacterial supernatants and
subsequently incubated with fluorescently labeled Fg. Whereas
WT supernatants attracted Fg to the surface of pre-opsonized
bacteria, Efb-deficient supernatants did not mediate complex
formation (Fig. 7B). This phenotype was restored in the
complemented strain. Then we studied whether endogenous Efb
could inhibit phagocytosis by neutrophils in vitro. Therefore we
Figure 4. Phagocytosis inhibition by Efb is independent of complement inhibition. A. Phagocytosis of fluorescently labeled S. epidermidis
and E. coli by purified human neutrophils in the presence of human plasma (5%) and Efb. B. Immunoblot detecting surface-bound C3b after
incubation of S. aureus with 5% human plasma in the presence of 5 mM EDTA or 0.5 mM Efb. Blot is a representative of 3 independent experiments. C.
Alternative pathway hemolysis of rabbit erythrocytes in 5% human plasma and Efb (mutants) (1 mM). Bars are the mean 6 se of three independent
experiments. **P,0.005 for Efb versus buffer (two-tailed Student’s t-test). D. Phagocytosis with a washing step. Fluorescent S. aureus was first
incubated with 5% serum to deposit complement. Bacteria were washed and subsequently mixed with neutrophils and Fg in the presence or
absence of Efb (0.5 mM). Graph is a representative of three independent experiments.
doi:10.1371/journal.ppat.1003816.g004
Anti-phagocytic Properties of Efb
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repeated the latter experiment (but using fluorescent bacteria and
unlabeled Fg) and subsequently mixed the bacteria with human
neutrophils. We found that supernatants of WT and complement-
ed strains inhibited phagocytosis, while Efb-deficient supernatants
did not influence this process (Fig. 7B). To mimic bacterial
phagocytosis during a natural infection, carrageenan-treated mice
were injected i.p. with GFP-expressing WT S. aureus or the Efb-
deficient mutant in their original broth culture and sacrificed 1 h
thereafter. Mice were subjected to peritoneal lavage and the
percentage of neutrophils with internalized staphylococci was
determined by flow cytometry. As depicted in Fig. 7D, the
Efb-deficient S. aureus strain was phagocytosed by neutrophils to a
significantly higher extent than the WT strain despite of the fact
that the amount of inoculated bacteria was comparable in both
groups (app. 26107). These observations demonstrate that the
levels of Efb produced by S. aureus are sufficient for preventing
phagocytosis in vivo.
Discussion
The coagulation system has a dual role in the host defense
against bacterial infections. On one hand, coagulation supports
Figure 5. Efb attracts Fg to the bacterial surface. A. ELISA showing that Efb can bind Fg and C3b at the same time. C3b-coated microtiter wells
were incubated with Efb (mutants) and, after washing, incubated with 50 nM Fg that was detected with a peroxidase-conjugated anti-Fg antibody
(Abcam). Graph is a representative of two independent experiments performed in duplicate. B. Binding of Alexa488-labeled Fg (60 mg/ml) to serum-
opsonized S. aureus in the presence of Efb (mutants) (0.5 mM). Graph represents mean 6 se of three independent experiments. *P,0.05, **P,0.005
for Efb versus buffer (two-tailed Student’s t-test). N.S. is not significant. C. Confocal analysis of samples generated in B (representative images). D. TEM
pictures of S. aureus incubated with 5% human plasma in the absence or presence of Efb (0.5 mM). Three representative images are shown.
doi:10.1371/journal.ppat.1003816.g005
Anti-phagocytic Properties of Efb
PLOS Pathogens | www.plospathogens.org 7 December 2013 | Volume 9 | Issue 12 | e1003816
innate defenses by entrapment and killing of invading bacteria
inside clots [26] or via the formation of small antibacterial and
pro-inflammatory peptides [27,28]. On the other hand, bacterial
pathogens can utilize coagulation proteins to protect themselves
from immune defenses. In this study, we find that S. aureus
effectively protects itself from immune recognition by secreting Efb
that specifically attracts Fg from the solution to the bacterial
surface creating a capsule-like shield (Figure 8). To accomplish
this, Efb forms a multi-molecular complex of soluble Fg and
surface-bound C3b. The fact that the levels of C3b at the bacterial
surface are high [29] and that Fg is an abundant plasma protein
(1.5–4.0 g/L) makes this a very efficient anti-phagocytic mecha-
nism. The Fg shield created by Efb effectively protects S. aureus
from recognition by phagocyte receptors. We found that the
attracted Fg does not only block the binding of C3b to its receptor,
but also hides the important opsonin IgG underneath the Fg
shield. We think that this information is critical for future vaccine
development against S. aureus. Generation of protective ‘opsoniz-
ing’ antibodies recognizing S. aureus surface structures is considered
to be an important goal of vaccination. However, these antibodies
will not function if they are protected underneath a layer of Fg. We
anticipate that including Efb in future vaccines might be beneficial
as it could prevent formation of this anti-phagocytic shield and
enhance the function of opsonizing antibodies. The fact that Efb is
conserved among S. aureus strains may make it a suitable vaccine
candidate [30].
Next to Efb, S. aureus secretes two other proteins that specifically
interact with the coagulation system: the S. aureus ‘coagulases’
named Coagulase and Von Willebrand factor binding protein are
secreted proteins that activate prothrombin in a nonproteolytic
manner and subsequently convert Fg into fibrin [31]. Thereby,
coagulases embed bacteria within a network of fibrin, protecting
them from immune recognition and facilitate formation of S. aureus
abscesses and persistence in host tissues [32]. Coagulase and Efb
are expressed at the same time during infection since they are both
regulated by the SaeR/S regulator for secreted (immune evasion)
proteins [25,33]. Based on our study, we hypothesize that Efb may
be highly important for proper functioning of Coagulase since Efb
can attract Fg to the bacterial surface. This way, Efb may aid
Coagulase-dependent fibrin formation to occur close to the
bacterial surface instead of in solution. Nevertheless our studies
also indicate that Efb can block phagocytosis in the absence of
prothrombin and Coagulase. However, in a more complex
environment the anti-phagocytic mechanisms of Efb and S. aureus
Coagulase might work synergistically. Furthermore, it seems
tempting to speculate that the ability of Efb to attract Fg to the
bacterial surface is also beneficial in other infection processes like
adhesion. Since Fg is an important constituent of the extracellular
matrix (ECM), Efb might also facilitate binding of C3b-opsonized
bacteria to the ECM. In fact, Efb was previously classified as an
adhesion molecule belonging to the group of SERAMs (secreted
expanded repertoire adhesive molecules) [34]. However, as a
secreted protein, Efb cannot facilitate bacterial adhesion if it
solely binds to Fg in the ECM without interacting with the
bacterial surface. Binding to C3b-labeled bacteria via the Efb C-
terminus might therefore be crucial for effective bacterial
adhesion to Fg.
The pathogenic potential of S. aureus is a result of its versatile
interactions with multiple host factors, evidenced by the fact that it
can survive at multiple sites of the body causing a wide range of
infections. At most body sites, S. aureus has to deal with cellular and
humoral components of the immune system. However, increasing
evidence now suggests that S. aureus protects itself from immune
defense by forming abscess communities surrounded by capsule-
like structures that prevent neutrophil invasion [35,36]. Our study
implicates that Efb might be crucial in the formation of these
capsules. Furthermore, our whole blood assays shows that Efb may
also play an important role in S. aureus survival in the blood
allowing it to spread to other sites of the body. Previous studies
using animal models have highlighted the critical role of Efb in S.
aureus pathogenesis. For instance, Efb delays wound healing in a
rat wound infection model [10] and is important for S. aureus
pneumonia and abscess formation in kidneys [23]. Our in vivo
studies corroborate the in vitro findings and suggest that complex
formation can occur under physiological conditions in vivo.
However, the available mouse models do not closely mimic this
process during clinical infections in humans. Efb is produced in
later stages of bacterial growth, thus the bacteria need time to
produce Efb before they come into contact with neutrophils. Since
neutrophils need to be recruited from the blood to the site of the
infection, there normally is time for Efb production and complex
formation, especially in the human host where an infection starts
with a low number of bacteria. In contrast, in available mouse
models the timing is much different as a high inoculum (up to 108
bacteria) is required to establish an infection and these high
numbers of bacteria trigger a strong inflammatory response
resulting in that the bacteria are already phagocytized before Efb
is produced. For this reason, we have mixed the bacteria with their
supernatants to ensure the presence of endogenous Efb during the
course of the experiments and have chosen a model in which
Figure 6. Efb prevents recognition of opsonic C3b and IgG. A–B. Flow cytometry assay detecting binding of soluble CR1 (A) or anti-IgG
antibody (B) to pre-opsonized S. aureus in the presence of buffer, Efb (0.5 mM) and/or Fg (200 mg/ml). C. Efb inhibits phagocytosis of encapsulated S.
aureus by human neutrophils. FITC-labeled S. aureus strain Reynolds (high capsule CP5 expressing strain) was incubated with human plasma and/or
Efb (0.5 mM) in the presence (dotted line) or absence (solid line) of polyclonal rabbit anti-CP5 antibody. All figures represent the mean 6 se of three
separate experiments. *P,0.05, **P,0.005 for Efb+Fg versus buffer (A,B) or Efb versus buffer (for dotted lines) (two-tailed Student’s t-test).
doi:10.1371/journal.ppat.1003816.g006
Anti-phagocytic Properties of Efb
PLOS Pathogens | www.plospathogens.org 8 December 2013 | Volume 9 | Issue 12 | e1003816
neutrophils are already attracted to the infection site to focus on
the anti-phagocytic activity of the molecule. Future studies are
needed to design and execute appropriate animal studies that
overcome the limitations of current models and better reflect the
clinical situation.
In summary, we describe that full-length Efb can inhibit
phagocytosis in a unique way through its dual interaction with
complement and Fg. Our study indicates that Efb is a highly




Study participants provided written informed consent in accor-
dance with the Declaration of Helsinki. Approval was obtained
from the medical ethics committee of the UMC Utrecht. Animal
experiments were performed in strict accordance with the
German regulations of the Society for Laboratory Animal
Science (GV-SOLAS) and the European Health Law of the
Federation of Laboratory Animal Science Associations (FELASA).
Figure 7. Endogenously produced Efb blocks phagocytosis via complex formation. A. Left. Immunoblot detecting Efb in 4 h and 20 h
culture supernatants of S. aureus Newman; fixed concentrations of His-tagged Efb were loaded as controls. Right. Immunoblot of 4 h culture
supernatants of S. aureus Newman (WT), an isogenic Efb deletion mutant (DEfb) and its complemented strain (DEfb+pEfb). Blots were developed
using polyclonal sheep anti-Efb and Peroxidase-labeled donkey anti-sheep antibodies. Blot is a representative of two independent experiments. B.
Flow cytometry analysis of the binding of Alexa488-labeled Fg to pre-opsonized S. aureus in the presence of 4 h culture supernatants (2-fold diluted)
or purified Efb (250 nM). C. In vitro phagocytosis of fluorescently labeled S. aureus by purified human neutrophils. Pre-opsonized S. aureus was first
incubated with 4 h culture supernatants (2-fold diluted) or purified Efb (250 nM) and subsequently mixed with Fg and neutrophils. D. In vivo
phagocytosis of GFP-expressing wild-type or Efb-deficient S. aureus strains by neutrophils in the mouse peritoneal cavity. Neutrophils were attracted
to the peritoneal cavity using carrageenan (i.p.) and subsequently injected with 300 ml of GFP-expressing wild-type (SA WT) or Efb-deficient (SADEfb)
S. aureus strains during the exponential phase of growth. The peritoneal lavage was collected 1 h thereafter and neutrophil phagocytosis was
analyzed by flow cytometry. Neutrophils were gated based on Gr-1 expression. Graphs in B–D represent mean 6 se of three independent
experiments. *P,0.05, **P,0.005 for WT versus Buffer or DEfb (two-tailed Student’s t-test).
doi:10.1371/journal.ppat.1003816.g007
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All experiments were approved by the ethical board Niedersa¨ch-
sisches Landesamt fu¨r Verbraucherschutz und Lebensmittelsicher-
heit, Oldenburg in Germany (Permit No. 33.9-42502-04-10/0296).
Bacterial strains, fluorescent labeling and supernatants
In this study we used the laboratory S. aureus strains Newman,
SH1000, Reynolds and Wood 46 (with low expression of Protein
A). The S. aureus strain KV27 and the S. epidermidis and E. coli
strains were clinical isolates obtained within the UMCU. Targeted
deletion (and complementation) of Efb in S. aureus Newman was
described previously in [23]. All strains were cultured overnight on
Tryptic Soy Blood Agar (BD) or Todd Hewitt Agar (with
appropriate antibiotics) at 37uC. The capsule-expressing S. aureus
strain Reynolds and its isogenic CP5-deficient mutant were a kind
gift from Jean Lee (Harvard Medical School, Boston, USA) [22].
To optimize capsule expression, strain Reynolds was grown on
Columbia Agar supplemented with 2% NaCl (CSA) for 24 h at
37uC. For fluorescent labeling of strains, bacteria were resus-
pended in PBS and incubated with 0.5 mg/ml FITC (Sigma) for
30 minutes on ice. Bacteria were washed twice with PBS,
resuspended in RPMI medium with HSA and stored at 220uC
until further use. For in vivo experiments, S. aureus Newman and the
Efb mutant were transformed with the pCM29 plasmid (kindly
provided by Alexander Horswill, University of Iowa) allowing
constitutive expression of the superfolder green fluorescent protein
(sGFP) via the sarAP1 promoter [37]. To isolate bacterial
supernatants, WT and mutant strains were cultured overnight in
Todd Hewitt Broth (THB) without antibiotics and subsequently
sub cultured in fresh THB for 4 h or 20 h. Cultures were
centrifuged at 13,000 rpm and collected supernatants were stored
at 220uC until further use.
Protein expression and purification
Recombinant Efb proteins were generated in E. coli as described
previously [12,13]. Briefly, (parts of) the efb gene from S. aureus
strain Newman (without the signal peptide) were amplified by
PCR and ligated into either the pGEX-5x-1 vector (GE
healthcare) or the pRSETB vector (Invitrogen) for N-terminal
fusions with glutathione S-transferase (GST) or polyhistidine
respectively. Mutations of the Fg and C3 binding domains were
introduced in pGEX plasmids containing full-length GST-Efb as
described previously [13]. Recombinant proteins were expressed
and purified according to the manufacturer’s manual. In all
experiments where wild-type Efb was compared with mutants, we
used GST-tagged Efb. Otherwise His-tagged Efb was used.
ELISA
Microtiter plates were coated with human C3b [38] or Fg,
blocked with 3% BSA-PBS, and incubated with 6 nM Efb for one
hour at room temperature. Efb binding was detected using
peroxidase-conjugated rabbit anti-GST polyclonal antibodies
(Abcam) and quantified using 0-phenylenediamine dihydrochlo-
ride (Sigma). To study formation of C3b-Efb-Fg complexes, C3b-
coated plates were incubated with Efb for one hour at room
temperature. After washing, human Fg (50 nM) was added and
detected through incubation with peroxidase-conjugated anti-Fg
antibodies (Abcam).
Preparation of Fg-D fragments
D fragments of Fg were generated by digestion of human Fg
(Enzyme research) with plasmin (Enzyme research, 10 mg/15 mg
Fg) in TBS containing 10 mM CaCl2 for 4 hours at 37uC as
described earlier [39] with modifications. D fragments (85 kD)
were purified by gel filtration on Sephacryl S-200 (GE Healthcare)
and analyzed by SDS-PAGE.
Purification of human blood products
For preparation of plasma, venous blood from 10 healthy
volunteers was collected in glass vacutainers (BD) containing the
anticoagulant lepirudin (50 mg/ml) [40]. To prepare serum, blood
Figure 8. Proposed mechanism for phagocytosis inhibition by Efb. Schematic picture of the proposed phagocytosis escape mechanism by
Efb. Left, Complement activation on the bacterial surface results in massive labeling of S. aureus with C3b molecules while Fg stays in solution. Right,
S. aureus secretes Efb, which binds to surface-bound C3b via its C-terminal domain (colored yellow). Using its N-terminus (green), Efb attracts Fg to
the bacterial surface. This way, S. aureus is covered with a shield of Fg that prevents binding of phagocytic receptors to important opsonins like C3b
and IgG.
doi:10.1371/journal.ppat.1003816.g008
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was collected in glass vacutainers (BD) without anticoagulant and
allowed to clot for 15 min at room temperature. Plasma and
serum were collected after centrifugation for 10 minutes at
4000 rpm at 4uC, pooled and subsequently stored at 280uC.
Complement-inactivated serum was prepared by incubation of
serum for 30 min at 56uC. Human neutrophils were isolated
freshly from heparinized blood using the Ficoll-Histopaque
gradient method [41] and used on the same day.
Mice
C57BL/6 female mice were purchased from Harlan-Winkel-
mann (Borchen, Germany) and used in experiments when they
were between 8 and 10 weeks of age. They were housed in micro
isolator cages and given food and water ad libitum.
Phagocytosis assays
Whole blood phagocytosis. FITC-labeled S. aureus KV27
(16108/ml) was incubated with freshly isolated human lepirudin
blood (50%) and buffer or Efb (0.5 mM) in RPMI-0.05% HSA for
25 min at 37uC. The reaction was stopped using FACS lysing
solution (BD Biosciences); samples were washed with RPMI-
0.05% HSA and analyzed by flow cytometry using a FACSCalibur
(BD). Gating of cells occurred on basis of forward and side scatter;
for each sample we measured the fluorescence intensity of 10,000
gated neutrophils. Phagocytosis was expressed as the percentage of
neutrophils that became fluorescent.
Phagocytosis with purified neutrophils and plasma/
serum. FITC-labeled bacteria (56107/ml) were mixed with
human serum or plasma for 2 min at 37uC in the presence or
absence of Efb. Freshly isolated neutrophils (56106/ml) were
added and phagocytosis was allowed for 15 min at 37uC. The
reaction was stopped by formaldehyde fixation and analyzed
by flow cytometry. Alternatively, phagocytosis mixtures were
cytospinned on glass slides and stained using Giemsa-based Diff-
Quick solution. To analyze killing, phagocytosis mixtures were
not fixed but incubated for an additional 90 minutes before they
were diluted into ice-cold water (pH 11) and incubated for
15 min on ice to enable neutrophil lysis. Viable bacteria were
quantified by colony enumeration. For Fg supplementation, 5%
serum was supplemented with 50–200 mg/ml human or mouse
Fg (kindly provided by Dr. Jay L. Degen; purified from plasma
of wild type and Fgc390–396A mice [21]). To analyze the
influence of bacterial supernatants on phagocytosis, FITC-
labeled S. aureus KV27 (2.56107 cfu) was pre-incubated with
human serum for 30 min at 37uC in Veronal Buffered Saline
containing Ca2+ and Mg2+ (VBS++). After washing in VBS++-
0.5% BSA, bacteria were incubated with (2-fold) diluted culture
supernatants or purified Efb (250 nM) for 1 hour at 37uC. After
washing, bacteria were incubated with purified Fg (60 mg/ml,
Invitrogen) in RPMI-HSA for 1 hour at 37uC and subsequently,
neutrophils were added (7.56105 cells) and phagocytosis was
allowed for 30 min at 37uC.
In vivo phagocytosis. S. aureus strain SH1000 [42] was
grown to mid-log phase, heat-inactivated for 60 min at 90uC, and
fluorescently labeled with carboxyfluorescein (Molecular Probes,
Go¨ttingen, Germany). To induce infiltration of neutrophils within
the peritoneal cavity, mice were treated i.p. with 1 mg of
carrageenan (Type IV1, Sigma) 4 and 2 days prior to bacterial
challenge. Subsequently, mice were injected i.p. with 200 ml of a
solution containing 108 heat-inactivated carboxyfluorescein-la-
beled S. aureus SH1000 and Efb (1 mM). To compare WT and
DEfb strains, mice were directly inoculated in the peritoneal cavity
with 300 ml of GFP-expressing WT or DEfb S. aureus cultures
grown to a late exponential phase. Mice were sacrificed 1 h
thereafter, and their peritoneum was lavaged with sterile PBS.
Lavage samples were centrifuged and pelleted cells were incubated
with purified anti-CD32 antibodies to block the FcR, followed by
PE-conjugated anti-mouse Gr-1 antibodies. Cells were washed
and quenched with trypan blue (2 mg/ml). Samples were
immediately subjected to flow-cytometric analysis using a
FACScan (Becton Dickinson, San Jose, California). Neutrophils
were gated according to their expression of Gr-1 antigen (FL2).
Phagocytosis was expressed as the percentage of neutrophils that
became fluorescent.
Alternative pathway hemolysis assay
Human serum (5%) was incubated with buffer or Efb proteins
(1 mM) in HEPES-MgEGTA (20 mM HEPES, 5 mM MgCl2,
10 mM EGTA) for 15 min at RT. Rabbit erythrocytes (Biotrading
Benelux B.V.) were added and incubated for 60 min at 37uC.
Mixtures were centrifuged and hemolysis was determined by
measuring the absorbance of supernatants at 405 nm.
Immunoblotting
To analyze C3b deposition on the bacterial surface, S. aureus
strain Wood46 (36108/ml) was incubated with 5% human
plasma in the presence of Efb (0.5 mM), EDTA (5 mM) or buffer
(HEPES++; 20 nM HEPES, 5 mM CaCl2, 2.5 mM MgCl2,
pH 7.4) for 30 min at 37uC shaking at 1100 rpm. Bacteria were
washed twice with PBS-0.1% BSA and boiled in Laemmli
sample buffer containing Dithiothreitol. Samples were subjected
to SDS-PAGE and subsequently transferred to a nitrocellulose
membrane (Millipore). C3b was detected using a peroxidase-
labeled polyclonal anti-human C3 antibody (Protos Immunor-
esearch, Burlingame, USA) and developed using Enhanced
Chemiluminescence (ECL, GE). To quantify Efb in bacterial
supernatants, His-Efb and supernatants were run together on an
SDS-PAGE gel. After transfer, blots were developed using a
polyclonal sheep anti-Efb antibody (kindly provided by Prof JI
Flock), peroxidase-labeled donkey anti-sheep antibodies (Fluka
Analytical) and ECL. Bands were quantified using ImageJ
software and linear regression analysis was performed using
GraphPad software.
Flow cytometry assays with S. aureus
S. aureus strain Wood46 (36108/ml) was pre-incubated with
human serum for 30 min at 37uC in VBS++ buffer, washed with
VBS++-0.5% BSA and incubated with Efb (0.5 mM) or 2-fold
diluted culture supernatants for 1 hour at 37uC shaking. After
another washing step, bacteria were incubated with Alexa-488
conjugated Fg (60 mg/ml, Invitrogen) for 1 hour at 37uC
shaking. Washed bacteria were analyzed by flow cytometry
using a FACSCalibur (BD). Bacteria were gated on the basis of
forward and side scatter properties and fluorescence of 10,000
bacteria was analyzed. Alternatively, we incubated pre-opsonized
bacteria with Efb (0.5 mM) and/or unlabeled Fg (200 mg/ml) for
1 hour at 37uC shaking. Washed bacteria were incubated with
soluble rCR1 (10 mg/ml, kindly provided by Prof. Atkinson,
Washington University, St. Louis, MO), FITC-labeled F(ab9)2
anti-human C3 antibody (Protos Immunoresearch) or anti-
human IgG antibody for 30 min at 37uC. CR1 was detected
using PE-labeled anti-CD35 antibodies (BD Pharmingen); the
IgG antibody was detected using goat-anti-mouse PE antibodies
(BD Pharmingen). Capsule expression on strain Reynolds was
analyzed by incubating bacteria with polyclonal anti-CP5 rabbit
serum and Phycoerythrin (PE)-conjugated goat anti-rabbit
antibody.
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Confocal microscopy
Samples were transferred to glass slides and air-dried.
Membrane dye FM 5-95 (Invitrogen) was added and slides
were covered with a coverslip. Confocal images were obtained
using a Leica TCS SP5 inverted microscope equipped with a
HCX PL APO 406/0.85 objective (Leica Microsystems, The
Netherlands).
Transmission electron microscopy
S. aureus strain Wood 46 (36108) was incubated with human
plasma (10%) in the presence or absence of Efb (0.5 mM) in
HEPES++ for 30 min at 37uC, washed once with PBS-1% BSA
and adsorbed to 100 mesh hexagonal Formvar-carbon coated
copper grids (Stork-Veco, Zoetermeer, NL). Samples were
contrasted with 0.4% uranyl acetate (pH 4.0) and 1.8% methyl-
cellulose [43] and analyzed in a JEOL 1010 transmission electron
microscope (JEOL Europe, Nieuw Vennep, the Netherlands) at
80 kV.
Statistics
Statistical analyses were performed using GraphPad Prism 4.0
package and the differences between groups were analyzed for
significance using the two-tailed Student’s t-test.
Accession number
The accession number for Efb in S. aureus Newman is
YP_001332103, locus NWMN_1069.
Supporting Information
Figure S1 Purified Efb inhibits killing of S. aureus in
human plasma. Killing of S. aureus by purified human
neutrophils in the presence of 5% human plasma and Efb
(0.15 mM). Data are mean 6 se of two independent experiments.
*P,0.05 for Efb versus buffer (two-tailed Student’s t-test).
(PDF)
Figure S2 Fg- and C3b-binding characteristics of Efb
mutants. ELISA experiments analyzing binding of Efb (mutants)
to Fg (A) or human C3b (B). Microtiter wells, coated with 0.25 mg
human Fg (A) or C3b (B), were incubated with Efb or Efb mutants
(both at 6 nM). Efb binding was detected using peroxidase-
conjugated rabbit anti-GST antibodies (Abcam). Data are mean6
se of two independent experiments.
(PDF)
Figure S3 Capsule expression. (FITC-labeled) S. aureus
strain Reynolds and its isogenic CP5-deficient mutant were
incubated with Rabbit-anti-CP5 antibodies and PE-labeled goat-
anti-rabbit antibodies. Antibody binding was quantified using flow
cytometry. Data are mean 6 se of two independent experiments.
(PDF)
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